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Abnormal activation of Wnt/b-catenin-mediated
transcription is associated with a variety of human
cancers. Here, we report that LATS2 inhibits onco-
genic Wnt/b-catenin-mediated transcription by
disrupting the b-catenin/BCL9 interaction. LATS2
directly interacts with b-catenin and is present on
Wnt target gene promoters. Mechanistically, LATS2
inhibits the interaction between BCL9 and b-catenin
and subsequent recruitment of BCL9, independent
of LATS2 kinase activity. LATS2 is downregulated
and inversely correlated with the levels of Wnt target
genes in human colorectal cancers. Moreover, noco-
dazole, an antimicrotubule drug, potently induces
LATS2 to suppress tumor growth in vivo by targeting
b-catenin/BCL9. Our results suggest that LATS2 is
not only a key tumor suppressor in human cancer
but may also be an important target for anticancer
therapy.INTRODUCTION
The Hippo signaling pathway plays a critical role in oncogenesis
by regulating cell proliferation, epithelial-mesenchymal transi-
tion, and apoptosis (Zhao et al., 2008, 2010; Wu et al., 2003;
Harvey et al., 2003). Mammalian LATS (large tumor suppressor)
1 and 2, the homologs of Wts in Drosophila, are serine/threonine
kinases and key components of the Hippo signaling pathway
(Dong et al., 2007; Xu et al., 1995; Justice et al., 1995; Yabuta
et al., 2000). In canonical Hippo signaling, LATS 1 and 2 phos-
phorylate YAP and promote YAP cytoplasmic retention and
degradation, resulting in inhibition of cell proliferation and onco-1650 Cell Reports 5, 1650–1663, December 26, 2013 ª2013 The Autgenesis (Huang et al., 2005; Zhao et al., 2008). Although most
studies have focused on canonical Hippo signaling, some
studies suggest that individual components of the Hippo
signaling pathway can regulate cell survival, oncogenesis, and
cytokinesis independent of the Hippo-YAP cascade (Zhao
et al., 2010). For example, LATS1 was found to regulate cytoki-
nesis by inhibiting LIMK1 (Yang et al., 2004), and LATS2 bound
to Mdm2 to activate p53, serving as a novel checkpoint for the
maintenance of proper chromosome number (Aylon et al.,
2006). Moreover, genetic studies showed that Lats1 and Lats2
may have unique functions inmouse development and oncogen-
esis. Although Lats1-deficient mice developed ovarian tumors
and soft tissue sarcomas (St John et al., 1999), the deletion of
Lats2 in mice resulted in embryonic lethality (McPherson et al.,
2004). Interestingly, Lats2-deficient mouse embryo fibroblasts
(MEFs) lost contact inhibition and displayed centrosome amplifi-
cation and genomic instability (McPherson et al., 2004).
The Wnt/b-catenin signaling pathway plays critical roles in
development, stem cell self-renewal, and oncogenesis (Mac-
Donald et al., 2009). The constitutive activation of Wnt/b-catenin
signaling has been found to be associated with a variety of
human cancers such as colorectal cancer, prostate cancer,
and squamous cell carcinoma (SCC) (Morin et al., 1997; Korinek
et al., 1997; You et al., 2002; Chen et al., 2001; Li and Wang,
2008). Wnt/b-catenin signaling promotes cell proliferation, sur-
vival, and invasive growth through b-catenin/Tcf-mediated tran-
scription (Morin et al., 1997; Korinek et al., 1997). In the absence
ofWnt/b-catenin signaling, Wnt target genes are silenced by Tcf/
Lef family proteins and corepressors of Groucho/TLE1 and
histone deacetylase 1 (HDAC1). Wnt signaling leads to an accu-
mulation of cytosolic and nuclear b-catenin. Nuclear b-catenin
stimulates gene transcription by recruiting chromatin-remodel-
ing complexes and coactivators (MacDonald et al., 2009).
Several transcription complexes or coactivators, including
BCL9 and Pygopus (PYGO), polymerase-associated factor 1hors
(PAF1), and SET1 (trithorax), have been identified to be recruited
by b-catenin (Parker et al., 2002; Mosimann et al., 2006; Kramps
et al., 2002). Importantly, BCL9 is highly expressed in human
tumor tissues, and the b-catenin/BCL9 complex has been iden-
tified as an important target for cancer therapy (Takada et al.,
2012). b-Catenin-mediated transcription is tightly regulated by
various signaling molecules and pathways. Because there is a
crosstalk between Hippo and Wnt/b-catenin signaling (Zecca
and Struhl, 2010; Varelas et al., 2010), we initially set out to
explore how the Hippo signaling pathway regulates Wnt/
b-catenin-mediated transcription. Unexpectedly, we found that
LATS2 was capable of directly inhibiting b-catenin/BCL9-
mediated transcription independent of the canonical Hippo-
YAP signaling cascade and its associated kinase activity.
LATS2 downregulation was found to be associated with the
development and metastasis of human colorectal cancer and
poor prognosis. Intriguingly, we found that nocodazole, a
chemotherapeutic drug that inhibits the polymerization of micro-
tubule, potently inhibited b-catenin/BCL9-mediated transcrip-
tion and tumor growth by inducing LATS2. Our results suggest
that LATS2 may suppress oncogenesis by targeting b-catenin/
BCL9 in addition to phosphorylating YAP.
RESULTS
LATS2 Inhibits Wnt/b-Catenin-Mediated Transcription
To explore whether LATS2 modulated Wnt/b-catenin-mediated
transcription, we utilized a SuperTopFlash (STopflash) reporter
assay that measures b-catenin/Tcf-mediated transcription (Li
and Wang, 2008). Overexpression of LATS2 significantly
inhibited b-catenin/Tcf-mediated transcription in human embry-
onic kidney (HEK) 293T cells induced by LiCl, an inhibitor of GSK-
3b (Figure 1A). Similarly, overexpression of LATS2 also inhibited
b-catenin/Tcf-mediated transcription induced by Wnt-3a (Fig-
ure 1B). Canonical Wnt ligands bind to Frizzled receptors and
LRP5/LRP6 receptors to stabilize cytosolic b-catenin, which is
involved in multiple signaling cascades. The increased b-catenin
translocates to the nucleus to activate gene transcription (Mac-
Donald et al., 2009; Townsley et al., 2004). Recently, Varelas
et al. (2010) showed that Hippo signaling inhibitedWnt/b-catenin
signaling by promoting an interaction between TAZ and DVL2,
which is the upstream of b-catenin. To determine the Wnt
signaling step that is inhibited by LATS2, we examined whether
LATS2 could directly inhibit STopflash reporter activity induced
by overexpression of b-catenin-S4A (b-Cat), which carries four
alanine substitutions in the GSK3b recognition site. Unexpect-
edly, overexpression of LATS2 also significantly inhibited
b-Cat-induced transcription, suggesting that LATS2 could act
on or downstream of b-catenin (Figure 1C). In contrast, overex-
pression of LATS1 did not inhibit b-Cat-induced transcription
(Figures S1A and S1B). Moreover, overexpression of LATS2
did not affect NF-kB or AP-1 reporter activities (Figure S1C).
To test whether endogenous LATS2 regulated b-catenin/Tcf-
mediated transcription, we utilized siRNA to knock down
LATS2. Western blot analysis confirmed that LATS2, but not
LATS1, was efficiently depleted (Figure 1D). The knockdown of
LATS2 significantly enhanced b-catenin/Tcf-mediated transcrip-
tion induced by Wnt-3a (Figure 1E). To confirm the specificity ofCell ReLATS2 siRNA, additional siRNA targeting different LATS2
sequence showed similar effects (Figures S1D and S1E). The
restoration of LATS2 expression abolished enhanced b-catenin/
Tcf-mediated transcription induced by LATS2 siRNA (Fig-
ure S1F). Moreover, we found that the knockdown of LATS2
also enhanced the expression of AXIN2 and DKK1, two well-
known Wnt target genes, induced by Wnt-3a (Figure 1F). To
determine whether LATS2 kinase activity was required for the
inhibition of Wnt/b-catenin signaling, we examined whether
the kinase-dead LATS2 mutant (LATS2-KD) could inhibit
b-catenin/Tcf-mediated transcription. Unexpectedly, overex-
pression of LATS2-KD also potently inhibited b-Cat-induced
transcription. To further confirm our results, we deleted the entire
kinase domain (amino acids 626–1,042) of LATS2 and found that
the N-terminal fragment (amino acids 1–625) of LATS2 (LATS2N)
also strongly inhibited b-Cat-induced transcription (Figure 1G).
Because TAZ had been found to inhibit Wnt/b-catenin signaling
(Varelas et al., 2010), we also examined whether the inhibition of
b-catenin-mediated transcription by LATS2 was dependent on
TAZ. However, the knockdown of TAZ did not affect LATS2-
mediated inhibition of b-Cat-induced transcription (Figures 1H
and 1I). Similarly, also the knockdown of YAP did not modulate
LATS2 inhibition (Figures 1H and 1I). Moreover, we found that
overexpression of YAP or TAZ did not affect inhibition of
b-catenin-mediated transcription (Figures S1G and S1H). Taken
together, our results suggest that LATS2 is capable of inhibiting
Wnt/b-catenin-mediated transcription independent of canonical
Hippo-YAP signaling.
LATS2 Directly Interacts with b-Catenin
Because LATS2 potently inhibited b-catenin-mediated tran-
scription, we first performed coimmunoprecipitation (coIP) to
examine whether LATS2 interacted with b-catenin. Flag-
b-catenin and HA-LATS2 were expressed either individually or
in combination in HK293T cells. The nuclear extracts were
prepared and immunoprecipitated with HA antibodies. Flag-
b-catenin could be detected in the immunoprecipitates with
HA antibodies or vice versa (Figure 2A). However, the interaction
between LATS2 and b-catenin wasmuch weaker or could not be
detected in the cytoplasm (Figure S2A). Because the
kinase domain deletion mutant LATS2N retained inhibition
of b-catenin-mediated transcription, we examined whether
LATS2N could bind to b-catenin. CoIP revealed that HA-
LATS2N, but not the C-terminal domain (amino acids 626–
1,042) of LATS2 (HA-LATS2C), interacted with b-catenin (Fig-
ure 2B). Further mapping revealed that amino acids 250–575 of
LATS2 were sufficient for interaction with b-catenin (Figures 2C
and 2D). Interestingly, unlike their kinase domains, the sequence
similarity between LATS1 and LATS2 in that region is extremely
low (Yabuta et al., 2000). b-Catenin contains the C-terminal
transactivation domain andmultiple arm repeats that play critical
roles in interactingwith and recruiting other transcription compo-
nents (MacDonald et al., 2009). We found that the LATS2 did not
interact with the transactivation domain of b-catenin (data not
shown). To further map the amino acid region of b-catenin that
was required for interaction, we generated three fragments of
b-catenin and found that b-catenin-133–694 containing arm
repeats was able to pull down LATS2 (Figure 2E) or vice versa.ports 5, 1650–1663, December 26, 2013 ª2013 The Authors 1651
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Figure 1. LATS2 Inhibits Wnt/b-Catenin-Mediated Transcription Independent of Hippo-YAP Signaling
(A) LATS2 inhibited STopflash reporter activities induced by LiCl in 293T cells. Experiments were performed at least three times. EV, empty vector.
(B) LATS2 inhibited STopflash reporter activities induced by Wnt-3a in 293T cells.
(C) LATS2 inhibited STopflash reporter activities induced by b-Cat in 293T cells.
(D) LATS2, but not LATS1, was knocked down by siRNA in 293T cells.
(E) LATS2 knockdown enhanced STopflash reporter activities induced by Wnt-3a.
(F) LATS2 knockdown enhanced the expression of AXIN-2 and DKK1 induced by Wnt-3a.
(G) LATS2 inhibited b-catenin-mediated transcription independent of its kinase activity.
(H) SiRNA knocked down TAZ and YAP.
(I) TAZ or YAP knockdown did not affect LATS2 inhibition of b-catenin-mediated transcription.
Values are mean ± SD for triplicate samples from a representative experiment. **p < 0.01, Student’s t test.
See also Figure S1.
1652 Cell Reports 5, 1650–1663, December 26, 2013 ª2013 The Authors
β-catenin 
-β-catenin 
Flag-
Flag
HA-LATS2
  HA-Lats2  - +     + 
  +     -     + 
-      +     + 
 +      -      + 
Input                            IP 
WB: Flag IP: HA 
IP: Flag        WB: HA 
       HA-LATS2-626-1042 
Flag-β-catenin      +     -       -       -       +      +      + 
Flag-β-catenin 
Input HA-LATS2 
Flag-β-catenin 
HA-LATS2 
IP:HA 
IP:Flag 
  Flag-β-catenin      +    -    -     -      -    -     +   +    +    +    + 
   Flag-β-catenin 
Input
IP:HA 
IP:Flag
D C 
Input                 GST  GST-β-catenin 
HA-LATS2 
G
HA-LATS2 
HA-LATS2  
Flag-β-catenin 
IP: HA 
WB: Flag 
E 
IP:Flag 
WB:HA 
WB: Flag
WB: HA 
HA-LATS2      +       +        +        +            +         +        +        + 
β-catenin        -                                            - 
Input                                     IP 
Input                  IP: IgG     IP: LATS2 
LiCl       -     +             -      +      -      + 
Wnt3a      -       +           -       +      -     + 
WB: β-catenin 
WB: β-catenin 
F 
     HA-LATS2-1-625 
       HA-LATS2-626-1042 
    Flag-β-catenin + + + - - 
- + - + - 
- - + - + 
+ + + - - 
- + - + - 
- - + - + 
Input IP: Flag 
WB: HA 
      HA-LATS2-1-625 
A B
Figure 2. LATS2 Interacts with b-Catenin
(A) LATS2 and b-catenin interacted when overexpressed in 293T cells. IP, immunoprecipitation; WB, western blot.
(B) The kinase domain of LATS2 was not required for the interaction between b-catenin and LATS.
(C and D) The amino acids 250–575 of LATS2 were required for interaction with b-catenin.
(E) b-Catenin-133–694 containing arm repeats interacted with LATS2. 293T cells were cotransfected with A-LATS2 and a variety of b-catenin deletion mutants.
(F) Endogenous b-catenin interacted with LATS2 upon LiCl or Wnt-3a stimulation.
(G) GST-b-catenin fusion protein pulled down HA-LATS2 protein in vitro.
See also Figure S2.
Cell Reports 5, 1650–1663, December 26, 2013 ª2013 The Authors 1653
The D162 andD164 residues of b-catenin are critical for the inter-
action between b-catenin and BCL9. However, the mutation of
these two sites did not affect b-catenin interaction with LATS2
(Figure S2B). To further determine whether endogenous LATS2
and b-catenin interact, we treated 293T cells with LiCl and iso-
lated the nuclear extracts from these cells. As shown in Figure 2F,
whereas LATS2 antibodies negligibly pulled down b-catenin
without stimulation, a significant amount of b-catenin was immu-
noprecipitated by LATS2 antibodies, as compared with IgG,
upon LiCl stimulation. Similarly, we found that Wnt-3a also
induced the complex formation between b-catenin and LATS2.
To further confirm our results and determine whether b-catenin
directly interacted with LATS2, we generated the recombinant
glutathione S-transferase (GST)-b-catenin fusion protein and
in-vitro-translated HA-LATS2 proteins. Our GST pull-down
assay revealed that b-catenin could directly bind to LATS2
in vitro (Figure 2G). Taken together, our results suggest that
LATS2 may inhibit b-catenin-mediated transcription by directly
interacting with b-catenin.
LATS2 Is Downregulated and Inversely Correlated with
b-Catenin-Mediated Transcription in Human Colorectal
Cancers
To examine whether LATS2 played an inhibitory role in human
colorectal cancer development, we strictly compared LATS2
expression in human colorectal cancer tissues with matched
adjacent normal colorectal tissues using human Colon Cancer
Screen-13 tissue microarray consisting of 50 samples. The
intensity of immunostaining was qualitatively measured using
Image-Pro Plus 6.0 image analysis software. Immunostaining
revealed that LATS2 expression was significantly decreased in
human colorectal cancer tissues compared tomatched adjacent
normal colorectal tissues (Figures 3A–3C). To examine whether
LATS2 expression was inversely correlated with human
colorectal progression, we stained LATS2 in human primary
colorectal tumors and metastatic colorectal tumors grown in
the liver or lymph node. LATS2 was nearly undetectable in
human colorectal cancer metastasis from liver and lymph node
compared with normal and primary colorectal cancer tissues
(Figures 3D–3H and S3).
To further determine whether LATS2 is an important tumor
suppressor gene in human colorectal cancer, we examined
whether LATS2 downregulation was associated with patient
prognosis using the colon cancer data set (GSE17537) in Gene
Expression Omnibus (GEO). Patients were dichotomized into
two groups as above or below median for LATS2 expression
value. Kaplan-Meier survival plot revealed that LATS2 expres-
sion was inversely associated with the survival times of patients
with colorectal cancers using the log rank test (p < 0.001; Fig-
ure 3I). Interestingly, patients with high LATS2 expression also
had longer recurrence-free survival times than those with low
LATS2 expression (p < 0.043; Figure 3J).
To determine LATS2 as a negative regulator of Wnt/b-catenin-
mediated transcription in human cancers, we immunostained
the expression of LATS2, b-catenin, AXIN2, andMMP7 in human
colorectal cancer tissue microarray consisting of 150 samples.
Pearson correlation analysis showed that LATS2 was found to
be inversely associated with tumor grade (Table S1). Using1654 Cell Reports 5, 1650–1663, December 26, 2013 ª2013 The Autb-catenin as a control variable, LATS2 was also inversely asso-
ciated with tumor grade (Table S2). Consistent with other
studies, we found that over 85%of TMA samples were positively
stained for cytoplasmic and nuclear b-catenin. Pearson correla-
tion analysis showed that b-catenin expression was correlated
with the levels of AXIN2 (R2 = 0.383; p < 0.001) and MMP7
(R2 = 0.333; p < 0.001) (Table S3). To determine whether
LATS2 negatively regulated the expression of AXIN2 and
MMP7 in vivo, partial correlation analysis was performed using
b-catenin as a control variable. We found that LATS2 expression
was inversely correlated with the levels of AXIN2 (R2 = 0.311;
p < 0.01) and MMP7 (R2 = 0.259; p < 0.01) (Table S4). Taken
together, our results suggest that LATS2 is a negative regulator
of oncogenic b-catenin-mediated transcription in human
colorectal cancers.
LATS2 Inhibits BCL9/BCL9L Recruitment by b-Catenin
To explore how LATS2 inhibited b-catenin-mediated transcrip-
tion, we performed chromatin immunoprecipitation (ChIP)
assays to determine whether LATS2would affect the recruitment
of b-catenin to the Wnt-regulated enhancer (WRE). As a strict
negative control, a region located in the open reading frame
(ORF) was also examined. We chose AXIN2 and DKK1 for our
ChIP assays because their promoters are tightly regulated by
Wnt/b-catenin. As shown in Figure 4A, overexpression of
LAST2 did not inhibit the level of b-catenin on the AXIN2 and
DKK1 promoters by overexpression of b-Cat. Conversely, the
knockdown of LATS2 did not affect b-catenin binding to the
AXIN2 and DKK1 promoters induced by LiCl (Figure 4B). Simi-
larly, the overexpression or knockdown of LATS2 did not modu-
late b-catenin binding to Axin-2 and DKK1 promoters induced by
Wnt-3a (Figures 4C and 4D). Interestingly, ChIP assays revealed
that LATS2, but not LATS1, was present on the AXIN2 and DKK1
promoters. The knockdown of LATS2, but not LATS1, reduced
its binding on the AXIN2 and DKK1 promoters (Figure 4E). To
activate transcription, b-catenin recruits an array of transcription
coactivators, including BCL9 and PYGO, p300/CBP, and the
PAF1 complex, to the Wnt target gene promoter (Parker et al.,
2002; Mosimann et al., 2006; Kramps et al., 2002; Townsley
et al., 2004; Gu et al., 2009). Thus, we explored whether LATS2
might interfere with b-catenin-mediated recruitment of transcrip-
tion coactivators to the Wnt target gene promoter. Overexpres-
sion or knockdown of LATS2 did not affect the recruitment
of CBP/p300 to the AXIN2 and DKK1 promoters induced by
Wnt-3a (data not shown). Importantly, overexpression of
LATS2 inhibited recruitment of BCL9 to the AXIN2 and DKK1
promoters induced by Wnt-3a (Figure 4F); the knockdown of
LATS2 enhanced BCL9 binding to the AXIN2 and DKK1 pro-
moters upon Wnt-3a or LiCl stimulation (Figures 4G and 4H).
To further confirm that LATS2 inhibited BCL9 recruitment by
b-catenin, we also performed coIP experiments to determine
whether LATS2 interfered with the interaction between b-catenin
and BCL9. As shown in Figure 5A, upon LiCl stimulation, a signif-
icant amount of b-catenin was pulled down by BCL9 or PYGO2
antibodies. BCL9L, a homolog of BCL9, was also found to
interact with b-catenin to promoteWnt target gene transcription.
We found that LiCl could also induce the interaction between
b-catenin and BCL9L. However, the b-catenin levels pulledhors
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Figure 3. LATS2 Expression Is Inversely
Associated with Human Colorectal Cancer
Development and Prognosis
(A and B) LATS2 expression was decreased in
human colorectal tumor tissues (B) compared with
adjacent normal tissues (A). TMA was stained with
LATS2 polyclonal antibodies.
(C) Quantitative measurement of LATS2 in human
colorectal tumor tissues and adjacent normal
tissues. The intensities of immunostaining were
quantitatively measured using Image-Pro Plus 6.0
image analysis software. **p < 0.01 (n = 50).
(D) Quantitative measurement of LATS2 in human
primary colorectal tumors and metastatic tumors
from the lymph node and liver. *p < 0.05 (n = 30).
(E–H) LATS expression was lost in humanmetastatic
colorectal tumors from the lymph node or liver. TMA
consisting of adjacent normal tissues (E), primary
tumors (F) and metastatic tumors from lymph node
(G) and liver (H) was stained with LATS2 polyclonal
antibodies.
(I) LATS2 expression was inversely associated with
the survival times of patients with colorectal cancer.
The published colon cancer data set (GSE17537)
containing patient follow-up information was used.
Kaplan-Meier survival plot was performed for dis-
ease-specific survival, and the log rank test was
applied to test the survival differences using SPSS
17.0 software.
(J) LATS2 expression was inversely associated with
the recurrence-free survival times of patients with
colorectal cancer.
See also Tables S1–S4 and Figure S3.down by BCL9, BLC9L, or PYGO2 antibodies were reduced
when LATS2 was overexpressed. Similarly, LAT2 also inhibited
the interaction between the active form of b-catenin, BCL9,
BCL9L, and PYGO2 as determined using antiactive form of
b-catenin. Overexpression of LATS2 inhibited the interaction be-
tween b-catenin, BCL9, BCL9L, and PYGO2 induced by Wnt-3a
(Figure 5B). In contrast, the knockdown of LATS2 enhancedCell Reports 5, 1650–1663, Db-catenin-BCL9/BCL9L complex formation
upon LiCl orWnt-3a stimulation (Figures 5C
and 5D). As a control, overexpression or
knockdown of LATS2 did not affect the
interaction between b-catenin and parafi-
bromin 1 (Figures 5A–5D). Finally, we per-
formed in vitro binding assays by using
human GST-b-catenin fusion proteins
and in-vitro-translated full-length LATS2,
BCL9, and BCL9L. Although GST-
b-catenin, but not GST, formed a complex
with BCL9, the addition of LATS2 disrupted
the BCL9 and b-catenin complex in a dose-
dependent fashion (Figure 5E). Similarly,
LATS2 also interfered with the BCL9L and
b-catenin complex in a dose-dependent
fashion (Figure 5F). We found that BCL9
and BCL9L were weakly expressed in
HT29 cells compared with other colorectalcell lines, including SW620, HCT116, and SW480 (Figure S4A).
Consistent with our findings, overexpression of LATS2N could
not inhibit STopflash reporter activities inHT29 cells (Figure S4B).
Of note, it was probably due to the induction of apoptosis that we
were able to overexpress the full-length LATS2 in HT29 cells. In
contrast, overexpression of LATS2N or LATS2 significantly
inhibited STopflash reporter activities in SW620 and SW480ecember 26, 2013 ª2013 The Authors 1655
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Figure 4. LATS2 Inhibits b-Catenin-Mediated Recruitment of BCL9 to the Wnt Target Gene Promoter
(A) 293T cells were cotransfected with b-catenin and LATS2 as indicated. The ChIP-enriched DNAswere quantitatively measured using real-time PCRwithAXIN-
2- and DKK1-specific primers. A region located in the ORF was utilized as a negative control.
(B) Cells were transfected with LATS2 or control siRNA for 48 hr and then treated with LiCl for 2 hr. ChIP assays were performed as described in (A).
(C) Cells were transfected with LATS2 for 24 hr and then treated with Wnt-3a. ChIP assays were performed as described in (A).
(legend continued on next page)
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Figure 5. LATS2 Inhibits the Interaction
between b-Catenin and BCL9
(A and B) LATS2 inhibited the interaction between
b-catenin and BCL9, BCL9L or PYGO2 induced by
LiCl (A) and Wnt-3a (B).
(C and D) LATS2 knockdown enhanced the inter-
action between b-catenin and BCL9, BCL9L or
PYGO2 induced by LiCl (C) and Wnt-3a (D).
(E) LATS2 inhibited the direct interaction between
b-catenin and BCL9 in vitro.
(F) LATS2 inhibited the direct interaction between
b-catenin and BCL9L in vitro.
See also Figure S4.and HCT116 cells (Figures S4C and S4D). LATS2 and LATS2N
were unable to inhibit b-catenin-mediated transcription in
HCT116 cells and 293T cells in which BCL9 and BCL9L were
depleted (Figures S4E and S4F). Moreover, overexpression of
LATS2 and LATS2N inhibited STopflash reporter activities in
both HCT116 p53+/+ and HCT116 p53/ cells, indicating that
their inhibition is independent of p53 (Figure S4G). LATS2N
also significantly inhibited the expression of Wnt target genes
in SW480 cells, but not in HT29 cells (Figures S4H–S4J).
The knockout of Lats2 in mice results in embryonic lethality
(McPherson et al., 2004). To further confirm the essential role(D) Cells were transfected with LATS2 or control siRNA and then treated with Wnt-3a. ChIP assays were pe
(E) Cells were transfected with LATS2 or control siRNA and chromatin immunoprecipitated with anti-LATS2
(F) Cells were transfected with LATS2 or vector control and then treated with Wnt-3a. ChIP assays were pe
(G and H) Cells were transfected with LATS2 or control siRNA for 48 hr and then treated withWnt-3a or LiCl. C
Values are mean ± SD for triplicate samples from a representative experiment. **p < 0.01, Student’s t test.
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mediated transcription, we utilized
Lats2/MEFs (Figure 6A). We found
that the basal levels of DKK2 were
increased in Lats2/MEFs compared
with Lats2+/+MEFs (data not shown). To
rule out the nonspecific effects of cell
immortalization, we attempted to reintro-
duce Lats2 back in Lats2/MEFs. Unfor-
tunately, we were unable to obtain stable
clones, probably due to growth suppres-
sion mediated by overexpression of
Lats2 through Hippo signaling. However,
we were able to stably express LATS2N
in Lats2/MEFs. Interestingly, western
blot analysis revealed that most LATS2N
protein was detected in nuclear fractions
in Lats2/MEFs expressing LATS2N
(Lats2/MEF/LATS2N) (Figure 6B).
STopflash report assays showed that
LATS2N significantly inhibited b-catenin/
Tcf-mediated transcription induced by
Wnt-3a (Figure 6C). Importantly, the ex-
pressions of Axin2 and Dkk1 induced
by Wnt-3a were significantly inhibited
in Lats2/MEF/LATS2N cells as com-
pared to control Lats2/MEF cellstransduced with empty vector (Lats2/MEF/V) (Figure 6D).
ChIP assays using LATS2 antibodies revealed that LATS2N
was detected in the Axin2 promoter (Figure 6E). Although
LATS2N did not impair b-catenin binding to the Axin2 promoter
induced by Wnt-3a, the recruitment of BCL9 and PYGO2 to the
Axin2 promoters induced by Wnt-3a was significantly reduced
in Lats2/MEF/LATS2N as compared with Lats2/MEF/V
(Figure 6G). Moreover, we found that ectopic expression of
LATS2N also inhibited human colorectal cell tumor growth
in vivo by inhibiting the b-catenin/BCL9 interaction (data not
shown).rformed as described in (A).
, anti-LATS1, or IgG.
rformed using BCL9 antibodies.
hIP assays were performed using BCL9 antibodies.
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Figure 6. LATS2 Kinase Domain Deletion Mutant Inhibits Wnt/b-Catenin-Mediated Transcription Lats2/MEFs
(A) Confirmation of LATS2 deletion in LATS2/MEFs by western blot.
(B) Lats2/MEFs were stably expressed with HA-LATS2N. Nuclear proteins were isolated from Lats2/MEFs expressing HA-LATS2N (MEF/LN) or control
vector (MEF/V) and probed with HA antibodies.
(C) LATS2N inhibited STopflash reporter activities induced by Wnt-3a.
(D) LATS2N inhibited the expression of Axin2 and Dkk1 induced by Wnt-3a.
(E and F) Both Lats2/MEF/V and Lats2/MEF/LATS2N cells were treatedwithWnt-3a and chromatin immunoprecipitatedwith anti-LATS2 (E) or anti-b-catenin
(F). The ChIP-enriched DNA was measured using real-time PCR with the Axin-2-specific primers.
(G) LATS2N inhibited the recruitment of BCL9 and PYGO2 to the Axin promoter induced by Wnt-3a.
Values are mean ± SD for triplicate samples from a representative experiment. **p < 0.01, Student’s t test.
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LATS2 Is Required for Nocodazole-Mediated Inhibition
of Tumor Growth by Targeting b-Catenin/BCL9
Nocodazole is a chemotherapeutic drug that exerts its effect in
tumor cells by inhibiting the polymerization of microtubules.
Elegant studies by Aylon et al. (2006) showed that nocodazole
potently induced LATS2 expression and inhibited cell growth.
Based on all the above-mentioned findings, we hypothesized
that nocodazole could exert its antitumor effect by inhibiting
Wnt/b-catenin signaling via the induction of LATS2 in addition
to targeting microtubules. As shown in Figure 7A, nocodazole
potently induced LATS2 expression in HEK293T cells. Consis-
tently, nocodazole significantly inhibited b-catenin-mediated
transcription induced by LiCl or b-Cat overexpression (Fig-
ure 7B). We also found that nocodazole induced LATS2, but
not LATS1, in a time-dependent manner in HCT116 cells (Fig-
ure 7C) and SW480 cells (Figure S5A). To test whether LATS2
was required for nocodazole-mediated inhibition of b-catenin-
mediated transcription, we utilized shRNA to knock down
LATS2. Western blot confirmed that shRNA efficiently knocked
down nuclear LATS2 proteins in HCT116 cells, whereas there
were no effects on nuclear b-catenin (Figure 7D). Although noco-
dazole significantly suppressed the expression of AXIN2 and
MMP7 in HCT116 cells expressing scramble shRNA (HCT116/
Scrsh), it could not affect the expression of AXIN2 and MMP7
in HCT116 cells expressing LATS2 shRNA (HCT116/LATS2sh)
(Figure 7E). The restoration of LATS2 or LATS2N in HCT116/
LATS2sh cells suppressed the expression of AXIN2 and
MMP7, confirming the specificity of LATS2 shRNA (Figure 7F).
Moreover, ChIP assays found that nocodazole induced LATS2
binding to the promoter of AXIN2 or MMP7 in HCT116/Scrsh
cells, but not in HCT116/LATS2sh cells (Figure 7G). Consistently,
we found that the occupancy of BCL9 on the promoter of AXIN2
or MMP7 was reduced in HCT116/Scrch cells, but not in
HCT116/LATS2sh cells, upon nocodazole treatment (Figure 7H).
In contrast, nocodazole did not interfere with b-catenin presence
on the promoter of AXIN2 or MMP7 (Figure 7I). The constitutive
activation of Wnt/b-catenin plays a critical role in human
colorectal tumor growth. Because nocodazole inhibited Wnt/
b-catenin by inducing LATS2, we further examined whether
LATS2 was required for nocodazole-mediated antitumor growth
in vivo. Both HCT116/Scrsh and HCT116/LATS2sh cells were
inoculated into nude mice that were subsequently treated with
nocodazole. Without nocodazole treatment, we found that the
tumors generated from HCT116/LATS2sh cells in nude mice
grew faster than those fromHCT116/Scrsh cells. Although noco-
dazole significantly suppressed tumor growth of HCT116/Scrsh
cells implanted in nude mice, it was unable to inhibit tumor
growth of HCT116/LATS2sh cells (Figures 7J and 7K), impli-
cating that nocodazole could target oncogenic b-catenin/BCL9
transcription in addition to other antitumor effects.
DISCUSSION
Given the critical roles of Wnt/b-catenin in development, stem
cell function, and oncogenesis, Wnt/b-catenin signaling is regu-
lated by a variety of signaling pathways and molecules
(MacDonald et al., 2009). LATS2 as tumor suppressor has
been found to be mutated or downregulated in several humanCell Recancers (Takahashi et al., 2005; Lee et al., 2009; Li et al.,
2011). However, themolecular mechanism by which LATS2 sup-
presses oncogenesis is not fully understood. Recent studies
suggest that LATS2 can inhibit oncogenesis by phosphorylating
the transcription factors YAP and TAZ in the canonical Hippo
signaling pathway. Our results reveal that LATS2 also is a nuclear
repressor of b-catenin-mediated transcription by disrupting
interaction between b-catenin and BCL9/PYGO2. Intriguingly,
the antimicrotubule compound nocodazole can inhibit tumor
growth by targeting b-catenin/BCL9 via the induction of
LATS2, providing insights into nocodazole-mediated antitumor
effects. Our results suggest that LATS2 may be an important
target for anticancer therapies.
Wnt/b-catenin signaling is abnormally activated in a variety of
human cancers. b-Catenin/TCF-mediated transcription plays
important roles in tumor development and progression. There
are several negative regulators that have been found to inhibit
b-catenin/TCF-mediated transcription. For example, the nemo-
like kinase (NLK) has been found to inhibit b-catenin/TCF binding
to DNA by phosphorylating LEF1 and TCF4 (Ishitani et al., 1999).
Here, we identified LATS2 as a nuclear repressor that targets the
interaction between b-catenin and the coactivator BCL9. Intrigu-
ingly, unlike NLK, LATS2 kinase activity was not required for the
inhibition of b-catenin/TCF-mediated transcription. Biochemical
and ChIP assays revealed that LATS2 inhibited the recruitment
of BCL9/PYGO2, but not b-catenin, to the Wnt target gene pro-
moters. BCL9 is the coactivator of b-catenin that has been found
to bind to the N-terminal arm repeats, whereas most of the tran-
scription coactivators interact with the C-terminal domain of
b-catenin (Kramps et al., 2002; Fiedler et al., 2008). It is possible
that LATS2 might interfere with BCL9 recruitment by interacting
with b-catenin. Supporting this notion, our in vitro binding assay
demonstrated that LATS2 could disrupt the BCL9 and b-catenin
complex.
Canonical Hippo signaling has been found to inhibit Wnt/
b-catenin signaling through TAZ, which interacts with DVL2 (Var-
elas et al., 2010). Both TAZ and YAP are phosphorylated by
LATS1 and LATS2. However, we found that knockdown of TAZ
did not affect LATS2 inhibition of b-catenin-mediated transcrip-
tion. Importantly, we found that LATS2 directly interacted with
b-catenin and occupied on the Wnt target gene promoters. Our
results suggest that nuclear LATS2 may play a direct role in the
suppression of oncogenesis. Although recent studies focus on
the phosphorylation of TAZ and YAP by LATS1 and LATS2 in
the cytoplasm, earlier studies have shown that LATS2 was
strongly detected in the nucleus (Yabuta et al., 2000). LATS2
has been found to inhibit androgen-regulated gene expression
by interacting with the androgen receptor in the nucleus (Powza-
niuk et al., 2004). Moreover, oncogenic H-Ras activation has
been found to induce LATS2 accumulation in the nucleus. The
inhibition of LATS2 expression overcomes a p53-dependent
stress checkpoint and apoptosis and promotes H-Ras-mediated
transformation (Aylon et al., 2009, 2010). Although the underlying
mechanisms that control nuclear accumulation of LATS2 are
unknown, it is possible that a variety of oncogenic signaling path-
ways may affect the subcellular localization of LATS2. In fact, we
found that LATS2 can be detected in both the cytoplasm and
nucleus of various tumor cell lines (data not shown). Althoughports 5, 1650–1663, December 26, 2013 ª2013 The Authors 1659
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Figure 7. Nocodazole Induces LATS2 to Block b-Catenin/BCL9-Mediated Transcription and Inhibits Tumor Growth In Vivo
(A) Nocodazole (Noc) induced LATS2 in HEK293 T cells by western blot.
(B) Nocodazole significantly suppressed b-catenin/Tcf-mediated transcription induced by LiCl or b-Cat overexpression. **p < 0.01.
(C) Nocodazole induced LATS2, but not LATS1, in a time-dependent manner in HCT116 cells.
(D) The knockdown of nocodazole-induced LATS2 by shRNA. Nuclear proteins from HCT116 cells were isolated and probed with LATS2 antibodies.
(E) Nocodazole suppressed the expression of AXIN2 and MMP7 dependent of LATS2. Both HCT116/Scrsh and HCT116/LATS2sh cells were treated with
nocodazole, and the expression of AXIN2 and MMP7 was determined by real-time RT-PCR. **p < 0.01.
(legend continued on next page)
1660 Cell Reports 5, 1650–1663, December 26, 2013 ª2013 The Authors
the nuclear localization signal (NLS) is not identified in LATS2,
interestingly, the kinase domain deletion mutant LATS2N was
predominantly detected in the nucleus, suggesting that NLS
may be present at the N terminal of LATS2. Alternatively, it is
possible that the kinase domain of LATS2 may promote the
cytoplasmic localization of LATS2. Consistent with the nuclear
function of LATS2, our in vivo tumor growthmodel demonstrated
that the LATS2N could potently suppress tumor growth by inhib-
iting b-catenin-dependent tumor growth.
Nocodazole is an antitumor agent that inhibits the polymeriza-
tion of microtubule and disrupts microtubule cytoskeleton. Pro-
longed treatment with nocodazole induces cell-cycle arrest and/
or apoptosis. Nocodazole has been found to induce LATS2 to
translocate to the nucleus where LATS2 binds to Mdm2 and sta-
bilizes p53, resulting in the activation of p53-mediated transcrip-
tion (Aylon et al., 2006). By identifying the crosstalk between
Wnt/b-catenin and LATS2, we found that nocodazole was a
potent inhibitor of Wnt/b-catenin signaling in addition to target-
ing microtubule cytoskeleton, providing insights into the molec-
ular mechanisms of nocodazole-mediated antitumor effect. In
human colorectal cancer, the tumor suppressor gene adenoma-
tous polyposis coli (APC) that plays an essential role in b-catenin
degradation is most commonly mutated. If APC is normally ex-
pressed, b-catenin is often found to be mutated. The outcome
of APC or b-catenin mutations results in the constitutive activa-
tion of b-catenin/Tcf-mediated transcription. As a therapeutic
strategy for treating human colorectal cancer, it is important to
target b-catenin-mediated transcription instead of the upstream
sites of the Wnt/b-catenin signaling pathway. Intriguingly, we
found that nocodazole inhibited oncogenic Wnt/b-catenin
signaling in a LATS2-dependent manner by disrupting the
b-catenin/BCL9 complex. Supporting this notion, the depletion
of LATS2 significantly compromised the inhibition of tumor
growth by nocodazole in vivo. Taken together, our results sug-
gest that LATS2 is not only an important tumor suppressor in
the development and metastasis of human colorectal cancer,
but may also be an important target for anticancer therapy.EXPERIMENTAL PROCEDURES
Plasmids, Oligonucleotides, and Antibodies
HA-LATS2, HA-LATS2KD, and YAP expression vectors were described previ-
ously (Zhao et al., 2008). LATS2 deletion mutant constructs were prepared
using the pcDNA3.1 (Invitrogen) or retroviral expression vector pQCXIP (Clon-
tech) by standard PCR subcloning. LATS1 expression vector was purchased
from Addgene. The plasmid STopflash reporters, pActin-b-galactosidase,
and CMV-b-galactosidase were used as previously described (Li and Wang,
2008). Primary antibodies were obtained from the following sources: b-catenin
(BD); anti-Flag and a-tubulin (Sigma-Aldrich); anti-HA (Covance); anti-TBP,(F) The restoration of LATS2 or LATS2N suppressed the expression of AXIN2 an
(G) Nocodazole induced LATS2 binding to the promoter of AXIN2 orMMP7 by Ch
nocodazole, and the promoter of AXIN2 or MMP7 was chromatin immunoprecip
(H) Nocodazole inhibited the occupancy of BCL9 on the promoter ofAXIN2 orMM
were treated with nocodazole, and the promoter of AXIN2 or BCL9 was chroma
(I) Nocodazole did not affect b-catenin binding to the promoter of AXIN2 or MMP
(J) LATS2 was required for nocodazole-mediated inhibition of tumor growth in nu
(K) Comparisons of actual tumor weights at the end of nocodazole treatment. At
*p < 0.05.
See also Figure S5.
Cell Reanti-BCL9 and anti-BCL9L (Abcam); anti-PYGO2 and anti-YAP (Santa Cruz
Biotechnology); anti-LATS1 and anti-LATS2 (Bethyl Laboratories); and anti-
LATS2 for immunostaining (McPherson et al., 2004). RT-PCR primers were
purchased from Sigma-Aldrich: human Dkk1 (50-agcctcttaactccttggca-30
and 50-tccatgtcactgggttccta-30 ); mouse Axin2 (50-CTGGCTCCAGAAGATCAC
AA-30 and 50-AGGTGACAACCAGCTCACTG-30); and mouse Dkk1 (50-GGT
GATGCAGGCACTAGAGA-30 and 50-AAGCCTGCACAAATGACAAG-30 ). The
sequences of ChIP primers were 50-GGCTGCGCTTTGATAAGGTCCT-30 and
50-ATCGCGAACGGCTGCTTATTTT-30 (mouse Axin2 WRE) and 50-TTAC
TGGCCAACGTGATGAT-30 and 50-GCTGTCAGGCACAGAGAGAG-30 (mouse
Axin2 negative control). The siRNA oligonucleotides of LATS2 (On-TargetPlus
siRNA) and YAP (On-TargetPlus SMARTpool siRNA) were purchased from
Thermo Fisher Scientific. The shRNA sequence for LATS2 knockdown is 50-GC
ACGCATTTTACGAATTC-30. All other sequences of RT-PCR and ChIP primers
were as previously described (Li and Wang, 2008).
Cell Culture, Transfection, and Luciferase Reporter Assay
HEK293T, HCT116, SW480, and SCC-1 cells were cultured in DMEM contain-
ing 10%FBS and antibiotics (streptomycin and penicillin) at 37C in a 5%CO2/
95% air atmosphere. MEF cells were maintained in DMEM supplemented with
15% FBS and NE-AAs (nonessential amino acids) at 37C, 5% CO2/95% air
atmosphere in a humidified incubator. For transient transfections, 53 105 cells
were seeded into 12-well plates for 12 hr and then transfected using
Lipofectamine 2000 reagents according to the manufacturer’s protocol
(Invitrogen). The total amount of DNA in each individual well was kept constant
by adding pcDNA3.1 empty vectors. Luciferase and b-galactosidase activity of
total cell lysates were determined using Luc-Screen and Galacto-Star kits
(Tropix), respectively.
For transfection of siRNA, 293T cells were plated at 40%–50% confluence
and transfected with various amounts of siRNA using Oligofectamine reagents
(Invitrogen). For siRNA combined with luciferase reporter experiments, 100 ng
of STopflash and 50 ng of CMV-b-galactosidase constructs were transfected
using Lipofectamine 2000 24 hr after the transfection of siRNA. To knock down
LATS2 in HCT116 and SW480 cells, LATS2 shRNA or control shRNA was
constructed in pLKO.1 vector (Addgene). To overexpress LATS2 or LATS2
deletionmutants in SW480 andMEF cells, LATS2was subcloned into retroviral
expression vector pQCXIP (Clontech) by standard PCR. To stably knock down
or overexpress LATS2, the cells were seeded in 6-well plates and incubated
overnight. The next day, respective viral particles were added evenly to the
plates. After 24 hr, themediumwas replacedwith freshmedium and incubated
overnight. From the next day onward, the cells were selected using puromycin
(2 mg/ml) for at least 3–4 days. The knockdown efficiency was determined
using immunoblot analysis.
Western Blot Analysis, Real-Time RT-PCR, CoIP, andGSTPull-Down
For each sample, 53 106 293T cells were lysed in lysis buffer for 10min on ice.
After centrifugation at 10,0003 g at 4C, the supernatants were incubatedwith
antibodies at 4C for 2 hr, followed by incubation with protein A or protein
G-Sepharose (GE Healthcare) for 1 hr. For nuclear coIP, the nuclear extracts
were prepared from 1.5 3 106 293T cells, as described previously. Immuno-
precipitates were washed three times with PBS and 0.1% NP40 buffer at
4C. For each GST pull-down assay, 2 mg of GST or GST fusion b-catenin
protein was incubated with glutathione beads (GE Healthcare) at 4C for
1 hr, followed by PBS wash. The precipitate beads were then incubated in
1 ml PBS with various amounts of in-vitro-translated BCL9 or LATS2 at 4Cd MMP7 in HCT116/LATS2sh cells.
IP assays. Both HCT116/Scrsh and HCT116/LATS2sh cells were treated with
itated with LATS2 antibodies. *p < 0.05.
P7 via the induction of LATS2. Both HCT116/Scrch and HCT116/LATS2sh cells
tin immunoprecipitated with BCL9 antibodies. *p < 0.05.
7.
de mice (n = 7–8). *p < 0.05.
the end of experiments, tumors from nude mice were dissected and weighted.
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overnight, followed by washing buffer for five times. Proteins bound to the
beads were eluted with SDS-loading buffer at 98C for 2 min and then
subjected to SDS-PAGE. Western blot analysis was performed as described
previously (Li and Wang, 2008).
Total RNA from each sample cell was purified using TRIzol reagents, and
cDNA was synthesized with random primers using SuperScript III (Invitrogen).
Quantitative RT-PCR analysis was carried out with iQ SYBR Green Supermix
(Bio-Rad) on an iCycler iQ real-time PCR detection system (Bio-Rad). GAPDH
levels were used as a loading control for real-time PCR.
ChIP Assays
ChIP assays were performed using a ChIP assay kit (Upstate Biotechnology)
according to the manufacturer’s protocol. Cells were incubated with a
dimethyl 3,30-dithiobispropionimidate-HCl (DTBP; Pierce) solution (5 mmol)
for 30 min on ice before formaldehyde treatment. For each ChIP reaction,
2 3 106 cells were used. All resulting precipitated DNA samples were quanti-
fied by real-time PCR. Data are expressed as the percentage of input DNA. The
primer sequences used for real-time PCRwere as previously described (Li and
Wang, 2008).
In Vivo Tumor Growth and Immunostaining
In vivo tumor growth in nude mice was performed as described previously (Li
and Wang, 2008). For nocodazole treatment, nude mice (seven to eight mice
per group) were inoculated with HCT116/Scrsh or HCT116/LATS2sh cells
for 6 days and then treated with nocodazole (10 mg/kg) every 2 days for
10 days. The animal protocol was approved by the Animal Research
Committee at the University of California, Los Angeles.
TMAswere purchased from LifeSpan Biosciences. Colon Cancer Screen-12
TMA contains 140 colon adenocarcinoma cores with stage/grade and 10
normal colon cores. Colon Cancer Screen-13 TMA contains 50 colon adeno-
carcinoma specimens with matched adjacent normal tissues. Colon Cancer
Screen-88 TMA contains 30 cases of adenocarcinoma, 30 metastasis, and 9
adjacent normal tissues. For immunostaining, antigen retrieval was performed
by pressure cooking in a Decloaking Chamber (Biocare Medical) in citrate
buffer (2.1 g/l citric acid [pH 6.0]) at 120C for 20 min). TMA was stained with
monoclonal antibodies against b-catenin (BD Biosciences), polyclonal anti-
bodies against LATS2, polyclonal antibodies against AXIN2, and polyclonal
antibodies against MMP7 at 4C overnight. We then incubated sections with
horseradish peroxidase-labeled polymer for 60 min, detected the immuno-
complexeswith AEC+chromogen (DakoEnVisionSystem), and counterstained
with hematoxylin. The intensity of immunostaining was measured by Image-
Pro Plus 6.0 image analysis software (Media Cybernetics). The intensity of
each image was calculated by normalizing the average integrated optical den-
sity (IOD) with the total selected area of interest (AOI). Correlation between the
expressions of different genes was calculated using SPSS 17.0 software. For
patient survival analysis, a colon cancer data set (GSE17537) containing
patient follow-up information was used (Smith et al., 2010). Patients were
dichotomized into two groups as above or belowmedian for LATS2 expression
value. Kaplan-Meier survival plot was performed for both disease-specific and
recurrence-free survival, and the log rank test was applied to test the survival
differences and calculate the p value using SPSS 17.0 software.
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